SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Tokyo hits record 10,000 COVID cases, Japan over 50,000 for first time

01/22/2022 | 04:29am EDT
COVID-19 pandemic in Tokyo

TOKYO (Reuters) -Tokyo recorded its fourth record number of daily COVID-19 infections on Saturday, breaking above 10,000, while Japan's exceeded 50,000 for the first time as the Omicron variant continues to spread rapidly.

The capital had 11,227 new coronavirus cases, the local government said a day after it reinstated curbs on mobility and business activity through Feb. 13.

Tokyo's case count, exceeding Friday's 9,699, were more than double the 4,561 logged a week earlier.

Three people in Tokyo died of COVID-19 and 12 were in serious condition on Saturday, the Tokyo government said.

Some 34.3% of hospital beds in the capital were being used by coronavirus patients. A rise in the occupancy rate to 50% would warrant a state of emergency with more severe restrictions, local officials have said.

Osaka prefecture announced 7,375 infections, a second consecutive record, and two deaths.

Infections nationwide totalled at least 50,200 as nearly 30 of Japan's 47 prefectures set records, broadcaster FNN reported.

As of Friday, 78.7% of Japan's population had been fully vaccinated, but only 1.5% had received a booster shot, according to the Prime Minister's Office.

The health ministry on Friday approved the use of the Pfizer vaccine for children aged five to 11 in an effort to ramp up the vaccination rate.

(Reporting by Kantaro Komiya; Editing by Raju Gopalakrishnan and William Mallard)

ę Reuters 2022
All news about PFIZER, INC.
01:00aChina Junshi's potential COVID drug shows promise in small trial
05/17DXC Technology Appoints Mike Salvino as Chairman, Succeeding Ian Read
05/17Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US
05/17INSIDER SELL : Pfizer
05/17Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children
05/17Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their ..
05/17FDA clears COVID booster shot for healthy kids ages 5 to 11
05/17Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi..
05/17Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 594 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,58x
Yield 2022 3,16%
Capitalization 288 B 288 B -
EV / Sales 2022 2,67x
EV / Sales 2023 3,50x
Nbr of Employees 79 000
Free-Float 58,2%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 51,34 $
Average target price 57,79 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-13.06%288 063
JOHNSON & JOHNSON4.53%468 600
ABBVIE INC.14.31%274 733
ROCHE HOLDING AG-14.96%260 807
MERCK & CO., INC.20.46%233 459